MedTrace Logo

Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy

NCT03000309 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-03-28

Study results available
· View outcomes & findings →

Summary

Sixteen week open label study of apremilast in combination with topical steroids with a four week safety follow up visit.

Conditions

Interventions

DRUG

Apremilast

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Derm Research, PLLC

    lead OTHER

Principal Investigators

  • Leon H. Kircik, M.D. · DermResearch PLLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-29
Primary Completion
2018-04-30
Completion
2018-04-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03000309 on ClinicalTrials.gov